4.0 Article

Leukemia inhibitory factor: A paracrine mediator of bone metabolism

期刊

GROWTH FACTORS
卷 30, 期 2, 页码 76-87

出版社

TAYLOR & FRANCIS LTD
DOI: 10.3109/08977194.2012.656760

关键词

Leukemia inhibitory factor; osteoblast; osteoclast; chondrocyte; gp130; oncostatin M

资金

  1. Victorian Government's OIS
  2. NHMRC (Australia)

向作者/读者索取更多资源

Leukemia inhibitory factor (LIF) is a soluble interleukin-6 family cytokine that regulates a number of physiologic functions, including normal skeletal remodeling. LIF signals through the cytokine co-receptor glycoprotein-130 in complex with its cytokine-specific receptor [LIF receptor (LIFR)] to activate signaling cascades in cells of the skeletal system, including stromal cells, chondrocytes, osteoblasts, osteocytes, adipocytes, and synovial fibroblasts. LIF action on skeletal cells is cell-type specific, and frequently dependent on the state of cell differentiation. This review describes the expression patterns of LIF and LIFR in bone, their regulation by physiological and inflammatory agents, as well as cell-specific influences of LIF on osteoblast, osteoclast, chondrocyte, and adipocyte differentiation. The actions of LIF in normal skeletal growth and maintenance, in pathological states (e. g. autocrine tumor cell signaling and growth in bone) and inflammatory conditions (e. g. arthritis) will be discussed, as well as the signaling pathways activated by LIF and their importance in bone formation and resorption.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.0
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据